Novel synthesis of CP-734432, an EP4 agonist, using Sharpless asymmetric dihydroxylation
摘要:
A novel and efficient asymmetric route to CP-734432, a lactam analog of PGE2, that shows selective agonism against the EP4 receptor subtype, is reported herein. The key steps include a Heck coupling to introduce the aryl ring at C-16 and a highly diastereoselective Sharpless asymmetric dihydroxylation to set the C-15 center. (C) 2009 Elsevier Ltd. All rights reserved.
Novel synthesis of CP-734432, an EP4 agonist, using Sharpless asymmetric dihydroxylation
摘要:
A novel and efficient asymmetric route to CP-734432, a lactam analog of PGE2, that shows selective agonism against the EP4 receptor subtype, is reported herein. The key steps include a Heck coupling to introduce the aryl ring at C-16 and a highly diastereoselective Sharpless asymmetric dihydroxylation to set the C-15 center. (C) 2009 Elsevier Ltd. All rights reserved.
EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS THEREOF
申请人:Merck Frosst Canada Ltd.
公开号:EP1912977A1
公开(公告)日:2008-04-23
[EN] EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS THEREOF<br/>[FR] AGONISTE DU RECEPTEUR EP4, COMPOSITIONS ET PROCEDES
申请人:MERCK FROSST CANADA LTD
公开号:WO2007014454A1
公开(公告)日:2007-02-08
[EN] This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions, which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts. [FR] Cette invention porte sur de puissants agonistes sélectifs du sous-type EP4 des récepteurs E2 de la prostaglandine, sur leur utilisation ou sur une formulation de ceux-ci destinée à être utilisée dans le traitement du glaucome et autres états liés à une pression intraoculaire élevée chez le patient. Cette invention porte également sur l'utilisation des composés de l'invention afin d'induire des processus de modelage et de remodelage osseux par les ostéoblastes et les ostéoclastes.
Novel synthesis of CP-734432, an EP4 agonist, using Sharpless asymmetric dihydroxylation
作者:Sajiv K. Nair、Jean J. Matthews、Stephan J. Cripps、Chunrong Ma、Elena Z. Dovalsantos、Alan W. Grubbs、Neal W. Sach、Wolter ten Hoeve、Han Koster、Erik J. Flahive、Steven P. Tanis、Matt Renner、Jim van Wiltenburg
DOI:10.1016/j.tetlet.2009.12.092
日期:2010.3
A novel and efficient asymmetric route to CP-734432, a lactam analog of PGE2, that shows selective agonism against the EP4 receptor subtype, is reported herein. The key steps include a Heck coupling to introduce the aryl ring at C-16 and a highly diastereoselective Sharpless asymmetric dihydroxylation to set the C-15 center. (C) 2009 Elsevier Ltd. All rights reserved.
EP4 Receptor Agonist, Compositions and Methods Thereof
申请人:Colucci John
公开号:US20090105234A1
公开(公告)日:2009-04-23
This invention relates to potent selective agonists of the EP
4
subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions, which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.